Interagency Patent Coordination and Improvement Act of 2025
The Interagency Patent Coordination and Improvement Act of 2025 would create a formal interagency task force between the U.S. Patent and Trademark Office (USPTO) and the Food and Drug Administration (FDA) to improve communication, information sharing, and technical coordination on patent matters involving human drugs and biological products. The bill directs the two agencies to enter into a memorandum of understanding and staff the task force with employees who have relevant technical, medical, scientific, and administrative expertise.
The task force would be responsible for sharing information about agency review processes, new drug and biologic approvals, prior art, scientific trends, and other information that could help patent examiners assess patentability and accuracy of applicant representations. It also creates a process for USPTO to request FDA information that may not be publicly disclosed, when needed for patent examination, and for USPTO to assist FDA in its ministerial patent-listing role. The bill includes confidentiality safeguards, notice to sponsors before certain information is shared, and procedures to prevent inadvertent disclosure.
The bill also requires the USPTO to report to Congress within four years on how often FDA information is shared and used in patent examinations, which methods are most useful, and whether Congress should change the task force’s mandate, funding, or operations. The report must also identify other federal agencies that might benefit from similar coordination with USPTO. In effect, the bill amends title 35 of the U.S. Code by adding a new section establishing the task force and related procedures.
Overall, the bill appears to have a generally positive, efficiency-oriented purpose, aiming to improve patent examination quality and interagency consistency, especially in the pharmaceutical and biotechnology sectors. Because there are no recorded votes or committee transcript excerpts provided, there is no documented opposition or support beyond the bipartisan sponsorship and the fact that the bill was reported with amendments and placed on the Senate calendar.
The bill would amend title 35 of the U.S. Code by adding a new section 1514 establishing the Interagency Task Force on Patents and by modifying USPTO’s duties in section 2(c) to require consultation with FDA on patent matters involving human drugs and biological products. It would create new statutory procedures for information sharing, confidentiality protections, sponsor notice, and reporting to Congress, while preserving FDA’s ministerial patent-listing function and not altering patent enforcement rights. The principal affected parties are USPTO, FDA, drug and biologic sponsors, and patent applicants and examiners in the life sciences sector.
The available legislative record suggests a generally favorable and pragmatic sentiment toward the bill. It was introduced by a bipartisan group of senators, reported by the Judiciary Committee with amendments, and advanced to the Senate Legislative Calendar, which indicates committee-level support. No votes, hearing testimony, or transcript excerpts are provided, so there is no documented floor debate or recorded opposition in the supplied materials.
The main potential points of contention are the scope of FDA-USPTO information sharing, the handling of confidential or nonpublic sponsor information, and whether the task force could affect the timing or substance of patent examination without intruding on FDA’s separate regulatory role. The bill anticipates these concerns by stating that USPTO may not interfere with FDA’s ministerial patent-listing function, by requiring confidentiality protocols and sponsor notice, and by preserving other remedies for unauthorized disclosure. Any disagreement would likely center on privacy, trade secret protection, and the practical limits of interagency coordination rather than on the bill’s overall objective.